argenx SE American Depositary Shares (ARGX) Financial Statements

argenx SE American Depositary Shares

ARGX · Nasdaq

	FY2019	FY2018	FY2017
Net Income	-$162.97M	-$66.64M	-$28.08M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$28.63	$27.16	$32.13	10	↑3 ↓3
Dec 2027	$35.33	$29.98	$41.43	12	↑2 ↓8
Dec 2028	$47.03	$38.86	$56.28	8	↑2 ↓0
Dec 2029	$57.90	$45.43	$77.90	5	↑1 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: ARGX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: Europe
Exchange: Nasdaq

argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas.

Key Issues

Bullish view

Zacks upgraded argenx to Rank #2 (Buy), explicitly citing growing optimism about its earnings prospects.

Bearish view

The stock still declined 3.18% across the supplied trading window, and the evidence provides no reported earnings figure or company update validating that optimism.

Analyst Consensus

See all

Buy

25 analysts

$901

Current

$1,182

Low

$1,140

Average

$1,182

High

Average target implies +26.51% versus the current price.

Earnings History

BeatMissNo estimate

argenx SE American Depositary Shares

Analyst Estimates

Peers